Meeting
2023 ASCO Annual Meeting
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
Authors
Matthew P. Goetz
Mayo Clinic, Rochester, MN
Matthew P. Goetz , Vera Jean Suman , Lida A. Mina , Pooja Prem Advani , John George Knecht , Heather Heather Fraser , Steven Carl Quay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT05607004
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS633)
DOI
10.1200/JCO.2023.41.16_suppl.TPS633
Abstract #
TPS633
Poster Bd #
454a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.
First Author: Daniella Audi Blotta
Poster
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
First Author: Yen-Shen Lu
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
Poster
2013 ASCO Annual Meeting
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+ HER2- metastatic breast cancer.
First Author: William John Gradishar